IPP Bureau
Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
By IPP Bureau - February 17, 2026
Alto met its enrollment goal with 83 patients across 13 US clinical sites
HanchorBio scores first FDA orphan drug tag for gastric cancer therapy
By IPP Bureau - February 17, 2026
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Beyfortus cuts RSV hospitalizations across two seasons in landmark study
By IPP Bureau - February 17, 2026
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder
By IPP Bureau - February 17, 2026
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Irish medtech firm InVera Medical wins EU nod for breakthrough vein treatment device
By IPP Bureau - February 17, 2026
Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
By IPP Bureau - February 17, 2026
Duvakitug was well tolerated and safety was consistent with the induction study
Moderna’s new Covid vaccine mNEXSPIKE wins European approval
By IPP Bureau - February 17, 2026
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
FDA grants priority review to Bristol Myers Squibb's Iberdomide for multiple myeloma
By IPP Bureau - February 17, 2026
Iberdomide has the potential to be the first approved CELMoD agent
Roche appoints Mark Dawson as new Head of Pharma Research and Early Development
By IPP Bureau - February 17, 2026
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Indian pharma market grew 10.2% yoy in January 2026
By IPP Bureau - February 17, 2026
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Biofrontera scores FDA filing acceptance for Ameluz PDT in skin cancer breakthrough
By IPP Bureau - February 16, 2026
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
Dewpoint Therapeutics selects groundbreaking MYC development candidate
By IPP Bureau - February 16, 2026
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
STADA & Bio-Thera bag European nod for Gotenfia
By IPP Bureau - February 16, 2026
Clinigen bags Japan's nod to human milk-based medicine for preterm infants
By IPP Bureau - February 16, 2026
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
Amgen scores EU nod for UPLIZNA in rare autoimmune disease
By IPP Bureau - February 16, 2026
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
